Maruyama Naomi, Miyoshi Yasuo, Taguchi Tetsuya, Tamaki Yasuhiro, Monden Morito, Noguchi Shinzaburo
Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita-shi, Osaka 565-0871, Japan.
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):408-14. doi: 10.1158/1078-0432.CCR-06-0267. Epub 2007 Jan 3.
Somatic mutations of PIK3CA, which encodes the p110alpha catalytic subunit of phosphatidylinositol 3-kinase, have recently been shown to play an important role in the pathogenesis and progression of human breast cancers. In this study, the frequency of PIK3CA mutations and their relationship with clinicopathologic and biological variables were investigated in Japanese breast cancers.
Mutational analysis of PIK3CA was done in 188 primary breast cancers of Japanese women. Relationship of these mutations with various clinicopathologic variables [histologic type, tumor size, histologic grade, lymph node status, estrogen receptor (ER)-alpha and progesterone receptor status, and prognosis], biological variables [phospho-AKT (pAKT) and HER2 expression determined by immunohistochemistry], and p53 mutation status was studied.
Missense mutations of PIK3CA were found in 44 of 158 invasive ductal carcinomas, 4 of 10 invasive lobular carcinomas, 1 of 4 mucinous carcinomas, 2 of 2 squamous carcinomas, and 2 of 2 apocrine carcinomas, but no mutation was found in 12 noninvasive ductal carcinomas. PIK3CA-mutated tumors were found to be more likely to be ER-alpha positive (P < 0.05) and pAKT positive (P < 0.05). There was no significant association between PIK3CA mutations and p53 mutation status. PIK3CA mutations were significantly (P < 0.05) associated with a favorable prognosis, and multivariate analysis showed that PIK3CA mutation status was a significant (P < 0.05) prognostic factor independent of the other conventional prognostic factors.
The frequency of PIK3CA mutations in Japanese breast cancers is similar to that of Caucasian breast cancers. Association of PIK3CA mutations with positive pAKT and positive ER-alpha suggests that PIK3CA mutations might exert their effects through activation of the phosphatidylinositol 3-kinase/AKT/ER-alpha pathway. PIK3CA mutations seem to have a potential to be used as an indicator of favorable prognosis.
编码磷脂酰肌醇3激酶p110α催化亚基的PIK3CA的体细胞突变,最近已被证明在人类乳腺癌的发病机制和进展中起重要作用。在本研究中,我们调查了日本乳腺癌中PIK3CA突变的频率及其与临床病理和生物学变量的关系。
对188例日本女性原发性乳腺癌进行了PIK3CA的突变分析。研究了这些突变与各种临床病理变量[组织学类型、肿瘤大小、组织学分级、淋巴结状态、雌激素受体(ER)-α和孕激素受体状态及预后]、生物学变量[通过免疫组织化学测定的磷酸化AKT(pAKT)和HER2表达]以及p53突变状态之间的关系。
在158例浸润性导管癌中的44例、10例浸润性小叶癌中的4例、4例黏液癌中的1例、2例鳞状细胞癌中的2例以及2例大汗腺癌中的2例中发现了PIK3CA的错义突变,但在12例非浸润性导管癌中未发现突变。发现PIK3CA突变的肿瘤更可能为ER-α阳性(P<0.05)和pAKT阳性(P<0.05)。PIK3CA突变与p53突变状态之间无显著关联。PIK3CA突变与良好预后显著相关(P<0.05),多变量分析显示PIK3CA突变状态是一个独立于其他传统预后因素的显著(P<0.05)预后因素。
日本乳腺癌中PIK3CA突变的频率与白种人乳腺癌相似。PIK3CA突变与pAKT阳性和ER-α阳性的关联表明,PIK3CA突变可能通过激活磷脂酰肌醇3激酶/AKT/ER-α途径发挥作用。PIK3CA突变似乎有潜力用作良好预后的指标。